These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 15701874

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P.
    Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
    [Abstract] [Full Text] [Related]

  • 4. Augmentation of radiation response with the vascular targeting agent ZD6126.
    Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1458-65. PubMed ID: 16488554
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
    Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R.
    Br J Cancer; 2007 Oct 08; 97(7):888-94. PubMed ID: 17848949
    [Abstract] [Full Text] [Related]

  • 7. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y.
    Cancer Res; 2000 Oct 01; 60(19):5565-70. PubMed ID: 11034104
    [Abstract] [Full Text] [Related]

  • 8. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.
    Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1526-37. PubMed ID: 17234361
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.
    Lund EL, Bastholm L, Kristjansen PE.
    Clin Cancer Res; 2000 Mar 01; 6(3):971-8. PubMed ID: 10741723
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC.
    Int J Radiat Oncol Biol Phys; 2007 Mar 01; 67(3):888-96. PubMed ID: 17293239
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
    Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP.
    Microvasc Res; 2006 Mar 01; 71(2):76-84. PubMed ID: 16530791
    [Abstract] [Full Text] [Related]

  • 15. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1512-7. PubMed ID: 12459379
    [Abstract] [Full Text] [Related]

  • 16. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Cancer Res; 2002 Jul 01; 62(13):3711-5. PubMed ID: 12097279
    [Abstract] [Full Text] [Related]

  • 17. ZD6126: a novel small molecule vascular targeting agent.
    Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1497-502. PubMed ID: 12459377
    [Abstract] [Full Text] [Related]

  • 18. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Clin Cancer Res; 2004 Nov 15; 10(22):7671-6. PubMed ID: 15570000
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.